île de France; Essonne;
Location of affected unit(s)
Les Ulis
Professional Services
Scientific, Architectural And Engineering Technical Activities
Scientific Research And Development
72.11 - Research and experimental development on biotechnology

209 jobs
Number of planned job losses
Job loss
Announcement Date
7 March 2023
Employment effect (start)
22 June 2023
Foreseen end date
31 December 2023


The Novartis group has announced the closure of its cell and gene therapy production site in Les Ulis (Essonne), which employs 209 people. Novartis bought the site in 2019 from the French Fractionation and Biotechnology Laboratory (LFB). The Swiss group had received 800,000 euros in subsidies from the stimulus plan to modernise the site.  The management announced this project to cease its CAR-T cell therapy production activities to employee representatives on 16 February. The information and consultation procedure for the implementation of a job protection plan began on 22 February. In accordance with the legislation, Novartis is required to look for a buyer before closing the site. Without a buyer by 22 June, 149 people will be made redundant then, and the remaining 60 - by the end of 2023.  At the end of 2022, Novartis had around 2,900 employees in France, including 1,436 jobs corresponding to medical sales representatives and the head office in Rueil-Malmaison (Hauts-de-Seine), with the remainder divided between two production sites. In Huningue (Alsace), around 800 people manufacture monoclonal antibodies, while in Les Ulis, 200 employees manufacture Kymriah, a cell therapy known as 'CAR T-Cell'. Novartis has alrerady announced a restructuring in January 2023, with 400 job cuts in France (FR-Novartis-2023a). At the day of the anouncement the management explained the two production sites located in Huningue and Les Ulis will not be affected. 



Eurofound (2023), Novartis CellForCure, Closure in France, factsheet number 108625, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/108625.